THW News and Press, Tekla World Healthcare Fund Shares of Beneficial Interest From 10/08/19

According to a new report from the nonprofit Institute for Clinical and Economic Review (ICER), AbbVie ( ABBV -0.6% ) and Roche ( OTCQX:RHHBY -1.6% ) were number one and two, respectively, in terms of the impact of their price increases on U.S. drug spending. More news on: AbbVie Inc...

There are an increasing number of fears hitting the minds of investors today. As I have discussed in past articles (such as this one ), there are a growing number of signs that the American economy is beginning to slow down. In addition to this, we have concerns about the ongoing trade war be...

This article was originally published 1 month ago. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence and investigation. Previous editions of the Report can be searched using the keyword "ce...

The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information...

In an interview with CNBC, Health Secretary Alex Azar revealed that the Trump administration is working on a plan that would allow the U.S. to import medicines from Canada, but offered no additional details as to how the plan would work. More news on: ProShares Trust - ProShares Ultra Na...

By a 19-9 vote, the Prescription Drug Pricing Reduction Act has advanced out of the Senate Finance Committee and will go before the full Senate this fall. The bill would cap out-of-pocket costs for medicines at $3,100 per year for Medicare beneficiaries beginning in 2022 and require drug m...

U.S. Senator Jeanne Shaheen (D-NH) has introduced a bipartisan bill , the Insulin Price Reduction Act, that she says will rein in skyrocketing costs of insulin while holding pharmacy benefit managers to account for their role in surging prices, adding that the cost of the most popular insul...

As someone that follows the financial markets on a daily basis, it sometimes feels as though there is a war going on between bears, who point to an increasing amount of data that points to a weakening economy, and bulls, who largely point to the Federal Reserve in one way or another as a major...

Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Heal...

Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers to disclose list prices in television advertisements. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & ...